(Q53335433)

13 May 2018

title

Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients. (English)

1 reference

13 May 2018

5

Leen Kim

1 reference

13 May 2018

In-Kwa Jung

8

In-Kwa Jung

1 reference

13 May 2018

Kwang-Yoon Suh

9

Kwang-Yoon Suh

1 reference

13 May 2018

Sook Haeng Joe

7

Sook-Haeng Joe

1 reference

13 May 2018

Heon-Jeong Lee

2

Heon-Jeong Lee

1 reference

13 May 2018

Min-Soo Lee

6

Min Soo Lee

1 reference

13 May 2018

author name string

Sun-Young Lee

1

1 reference

13 May 2018

Yong-Ku Kim

3

1 reference

13 May 2018

Seung-Hyun Kim

4

1 reference

13 May 2018

Hyung-Kyu Kim

10

1 reference

13 May 2018

publication date

1 July 2004

1 reference

13 May 2018

Journal of Psychosomatic Research

published in

1 reference

13 May 2018

volume

57

1 reference

13 May 2018

issue

1

1 reference

13 May 2018

page(s)

5-10

1 reference

13 May 2018

Chronic renal failure, dialysis, and neuropsychological function.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Neurocognitive function in chronic hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Improvement of brain function in hemodialysis patients treated with erythropoietin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

A neuropsychological battery for epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

An Inventory for Measuring Depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

The MOS 36-ltem Short-Form Health Survey (SF-36)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Haemoglobin--is more better?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Depression in patients with chronic renal disease: what we know and what we need to know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3999%2803%2900528-2

10.1016/S0022-3999(03)00528-2

7 January 2021

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

15256289

1 reference

13 May 2018